We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+42.6%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$376M
AUM Growth
+$212M
Cap. Flow
+$116M
Cap. Flow %
30.74%
Top 10 Hldgs %
99.83%
Holding
13
New
3
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$76.7M
2
ADCT icon
ADC Therapeutics
ADCT
+$20.5M
3
MRUS
Merus
MRUS
+$10.1M

Top Sells

Rank Stock Value
1
CTMX icon
CytomX Therapeutics
CTMX
+$6.56M
2
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Miscellaneous 11.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
1
DELISTED
Repare Therapeutics
RPTX
$74.1M 19.7%
+2,388,337
New +$76.7M
HARP
2
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$64.7M 17.21%
389,842
– –
TCRR
3
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$51.8M 13.77%
3,370,982
– –
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$37.4M 9.96%
2,331,534
– –
GTHX
5
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$34.5M 9.18%
1,423,794
– –
ADCT icon
6
ADC Therapeutics
ADCT
$146M
$25.3M 6.72%
+539,648
New +$20.5M
TPTX
7
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$19.9M 5.3%
308,686
– –
YMAB
8
DELISTED
Y-mAbs Therapeutics
YMAB
$14.6M 3.87%
337,291
– –
MRUS
9
DELISTED
Merus
MRUS
$11.3M 3%
+700,879
New +$10.1M
AUTL
10
Autolus Therapeutics
AUTL
$623M
$637K 0.17%
39,740
– –
CTMX icon
11
CytomX Therapeutics
CTMX
$699M
– –
-855,437
Closed -$6.56M
VIRX
12
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-80,283
Closed -$1.17M

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2020 Portfolio in Review

As of Q2 2020, MPM BioImpact held 13 positions worth $376M, up 130% from $164M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM BioImpact deployed $116M of net new capital in Q2 2020, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Repare Therapeutics: 2,388,337 shares worth $74.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was CytomX Therapeutics, an estimated $6.56M sold.

  • MPM BioImpact's largest Q2 2020 buy was Repare Therapeutics: 2,388,337 shares worth $74.1M.
  • MPM BioImpact fully exited CytomX Therapeutics in Q2 2020, selling an estimated $6.56M.
  • MPM BioImpact's ten largest holdings make up 100% of its $376M portfolio in Q2 2020.
  • MPM BioImpact opened 3 new positions and closed 2 in Q2 2020.
  • MPM BioImpact's portfolio value rose 130% quarter-over-quarter to $376M.

Based on MPM BioImpact's 13F filing for Q2 2020, filed 12 Aug 2020.